We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA’s Oncology Review Division Conducting Assessment of Accelerated Approvals
FDA’s Oncology Review Division Conducting Assessment of Accelerated Approvals
The FDA’s Oncology Center for Excellence is scrutinizing Accelerated Approvals granted for cancer indications in an initiative that’s led to multiple indication withdrawals by companies whose late-stage trials failed to meet primary endpoints.